candesartan has been researched along with Cardiomyopathy, Congestive in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reverse ventricular remodeling obtained with carvedilol, ramipril/candesartan, and spironolacton is associated with decreases in left ventricular end-diastolic volume, left ventricular end-systolic volume, tenascin-C levels, and NT-proBNP levels." | 2.78 | Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. ( Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R, 2013) |
| "Treatment with candesartan completely abrogated the emergence of the enlarged cells but did not reverse the Ito, and IKur in normal-sized cells in DCM hearts." | 1.40 | Effects of candesartan on electrical remodeling in the hearts of inherited dilated cardiomyopathy model mice. ( Daida, H; Inoue, H; Konishi, M; Kurebayashi, N; Morimoto, S; Murayama, T; Nakazato, Y; Odagiri, F; Sakurai, T; Shioya, T; Sugihara, M; Suzuki, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarli, B | 1 |
| Topsakal, R | 1 |
| Kaya, EG | 1 |
| Akpek, M | 1 |
| Lam, YY | 1 |
| Kaya, MG | 1 |
| Odagiri, F | 1 |
| Inoue, H | 1 |
| Sugihara, M | 1 |
| Suzuki, T | 1 |
| Murayama, T | 1 |
| Shioya, T | 1 |
| Konishi, M | 1 |
| Nakazato, Y | 1 |
| Daida, H | 1 |
| Sakurai, T | 1 |
| Morimoto, S | 1 |
| Kurebayashi, N | 1 |
| Baumwol, J | 1 |
| Lam, K | 1 |
| Maiorana, AJ | 1 |
| Watanabe, K | 1 |
| Juan, W | 1 |
| Narasimman, G | 1 |
| Ma, M | 1 |
| Inoue, M | 1 |
| Saito, Y | 1 |
| Wahed, MI | 1 |
| Nakazawa, M | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Tachikawa, H | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Yamamoto, T | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
1 trial available for candesartan and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilat | 2013 |
4 other studies available for candesartan and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Effects of candesartan on electrical remodeling in the hearts of inherited dilated cardiomyopathy model mice.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Remodeling; Benzimidazoles; Biphenyl Compounds; Ca | 2014 |
Successful explant of a continuous-flow left ventricular assist device after two years of circulatory support.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Diuretics; Exe | 2014 |
Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2003 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |